| Sep 5 |
IN8bio cuts staff and pipeline to focus on AML cell therapy
|
| Sep 4 |
IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia
|
| Aug 29 |
IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 14 |
INAB: AML & GBM Clinical Update
|
| Aug 12 |
IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100
|
| Aug 9 |
IN8bio GAAP EPS of -$0.19
|
| Aug 8 |
IN8bio Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
|
| Jun 24 |
IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
|
| Jun 17 |
INAB: INB-100 Update at EHA24 ¡Olé!
|
| Jun 14 |
IN8bio Decline After Favorable Leukemia Results Could Be Profit-Taking
|
